(HealthDay)—Stereotactic ablative radiation therapy (SABR) for recurrent oligometastatic cancer is a feasible and tolerable treatment option, according to a phase 2 study published in the January issue of the International Journal of Radiation Oncology, Biology, Physics.
* This article was originally published here
